About Eukaryotic translation initiation factor 2 subunit 3
Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3) is a protein
from Homo sapiens identified by UniProt accession
P41091, 472 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 2 subunit 3 |
| UniProt accession | P41091 |
| Gene | EIF2S3 |
| Organism | Homo sapiens |
| Length | 472 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (45)
Diseases linked to this target (Open Targets).
- MEHMO syndrome · score 0.81
- diabetes mellitus · score 0.37
- benign prostatic hyperplasia · score 0.28
- hypopituitarism · score 0.19
- Glucose intolerance · score 0.18
- genetic disorder · score 0.18
- lung adenocarcinoma · score 0.05
- hepatocellular carcinoma · score 0.04
- Intellectual disability · score 0.02
- Microcephaly · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41091-F1 | alphafold | PREDICTED | 85.14 | — |
Amino-acid sequence (472 residues)
MAGGEAGVTL GQPHLSRQDL TTLDVTKLTP LSHEVISRQA TINIGTIGHV AHGKSTVVKA ISGVHTVRFK NELERNITIK LGYANAKIYK LDDPSCPRPE CYRSCGSSTP DEFPTDIPGT KGNFKLVRHV SFVDCPGHDI LMATMLNGAA VMDAALLLIA GNESCPQPQT SEHLAAIEIM KLKHILILQN KIDLVKESQA KEQYEQILAF VQGTVAEGAP IIPISAQLKY NIEVVCEYIV KKIPVPPRDF TSEPRLIVIR SFDVNKPGCE VDDLKGGVAG GSILKGVLKV GQEIEVRPGI VSKDSEGKLM CKPIFSKIVS LFAEHNDLQY AAPGGLIGVG TKIDPTLCRA DRMVGQVLGA VGALPEIFTE LEISYFLLRR LLGVRTEGDK KAAKVQKLSK NEVLMVNIGS LSTGGRVSAV KADLGKIVLT NPVCTEVGEK IALSRRVEKH WRLIGWGQIR RGVTIKPTVD DD
Explore Eukaryotic translation initiation factor 2 subunit 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets